Kratom

Kratom (Mitragyna speciosa) is a tropical evergreen tree of the Rubiaceae family — the same botanical family as coffee (Coffea). Native to Southeast Asia, where it grows indigenously in Thailand, Indonesia, Malaysia, Myanmar, and Papua New Guinea, kratom has been used in traditional medicine and as a work-enhancement aid for centuries. Workers in the region historically chewed fresh leaves or brewed them into tea to combat fatigue, increase endurance, and relieve pain during physically demanding labor.

Chemistry and Alkaloids

Kratom contains at least 54 identified alkaloids, with the primary psychoactive constituents being mitragynine and 7-hydroxymitragynine (7-HMG).

• Mitragynine (C₂₃H₃₀N₂O₄, 398.50 g/mol) is the dominant alkaloid, accounting for up to 66% of total alkaloid content in Thai varieties and approximately 12% in Malaysian varieties. It is a tetracyclic indole alkaloid structurally related to yohimbine and voacangine.
• 7-Hydroxymitragynine (C₂₃H₃₀N₂O₅, 414.50 g/mol) is a minor constituent (less than 2% of total alkaloid content) but possesses significantly higher potency at the mu-opioid receptor — approximately 13-fold greater analgesic potency than morphine in animal models. It is also produced as an active metabolite of mitragynine via hepatic oxidation.

Other notable alkaloids include speciociliatine, paynantheine, speciogynine, corynantheidine, mitraphylline, and rhynchophylline. Total alkaloid concentration in dried leaves typically ranges from 0.5% to 1.5% by weight, though this varies considerably depending on geographic origin, maturity of the leaves, and drying method.

Pharmacology and Mechanism of Action

Kratom's pharmacology is unusually complex, reflecting its multi-receptor activity:

• Both mitragynine and 7-HMG are partial agonists at the μ-opioid receptor (MOR), which accounts for the analgesic and euphoric effects. Unlike full agonists such as morphine or fentanyl, their partial agonist nature provides a relative ceiling effect on respiratory depression — though this should not be mistaken for complete safety.
• Both compounds act as competitive antagonists at δ-opioid and κ-opioid receptors, with mitragynine showing much lower affinity for the κ-receptor (Ki: 1,100 nM) compared to the μ-receptor (Ki: 7.24 nM).
• Mitragynine also interacts with α₂-adrenergic, 5-HT₂C and 5-HT₇ serotonin, D₂ dopamine, and A₂A adenosine receptors. This multi-receptor profile may explain the stimulant-like effects observed at lower doses, which are not mediated through typical stimulant mechanisms such as monoamine reuptake inhibition.
• Kratom contains rhynchophylline, a non-competitive NMDA receptor antagonist, which may contribute to its dissociative and analgesic properties.
• Both mitragynine and 7-HMG display G-protein-biased agonism, favoring G-protein signaling pathways independent of β-arrestin recruitment. However, recent evidence suggests it is the low intrinsic efficacy at the mu-opioid receptor, rather than signaling bias, that is primarily responsible for kratom's improved side-effect profile relative to traditional opioids.

Mitragynine is primarily metabolized in the liver via CYP3A4 and CYP2D6 enzymes and is also a significant inhibitor of both enzymes. This creates an important concern for drug interactions, as many common medications depend on these pathways for metabolism. The oral bioavailability is estimated at approximately 21–30%, and the elimination half-life ranges from 7 to 39 hours — considerably longer than most traditional opioids.

Dose-Dependent Effects

Kratom is notable for producing markedly different effects depending on dose, which reflects the interaction of its various alkaloids across multiple receptor systems:

• Low doses (0.5–2 g): Predominantly stimulant effects — increased alertness, physical energy, talkativeness, sociability, and mild euphoria. Users report effects comparable to a strong cup of coffee, likely mediated through adrenergic and dopaminergic activity.
• Moderate doses (2–4 g): A mixed profile emerges, with opioid-like warmth and well-being combined with some residual stimulation. Analgesic effects become more pronounced.
• High doses (4–8 g+): Opioid-like effects dominate — significant sedation, analgesia, euphoria, and a general feeling of contentment. Nausea and the "wobbles" (dizziness and difficulty focusing) become more likely.

Subjective Effects

Common subjective effects reported by users include:

• Stimulant range: Increased motivation, enhanced mood, greater sociability, physical energy, and mild euphoria
• Opioid range: Warmth, contentment, pain relief, drowsiness, and a dreamy relaxed state
• Negative effects: Nausea and vomiting (especially at higher doses), constipation, dry mouth, loss of appetite, dizziness ("the wobbles"), sweating, and itching

The effects typically begin within 10–40 minutes of oral consumption and last 2–5 hours, with aftereffects persisting for up to 12 hours. The variability is influenced by stomach contents, tolerance, and the specific blend of alkaloids in a given batch or variety.

Tolerance, Dependence, and Withdrawal

Kratom carries a meaningful risk of physical dependence, particularly with regular daily use. In one survey, 25.5% of kratom consumers met criteria consistent with a substance use disorder diagnosis. Tolerance can develop within the first few weeks, and dose escalation of 4- to 10-fold has been documented within early use periods.

Withdrawal symptoms resemble those of opioid withdrawal, though they are generally considered milder. They include: loss of appetite, weight loss, insomnia, muscle spasms and bone pain, irritability, restlessness, and increased yawning. For most users, acute withdrawal symptoms last fewer than 3 days, but psychological cravings may persist longer.

Cross-tolerance exists between kratom and traditional opioids. Mice rendered tolerant to 7-hydroxymitragynine show cross-tolerance to morphine and vice versa, and naloxone-precipitated withdrawal occurs equally in both cases.

Harm Reduction

• Hepatotoxicity: Chronic kratom use can cause liver injury, with symptoms including abdominal discomfort, dark urine, itching, and jaundice. The latency is typically 1–8 weeks after beginning regular use.
• CYP enzyme inhibition: Kratom significantly inhibits CYP3A4, CYP2D6, and CYP1A2. This can dangerously elevate blood levels of many common medications.
• Contamination risk: In 2018, the FDA issued a mandatory recall of kratom products linked to a multistate Salmonella outbreak affecting 199 people. Unregulated supply chains mean adulteration with synthetic opioids (including fentanyl and O-desmethyltramadol) has been documented.
• Pregnancy: Neonatal abstinence syndrome has been documented in infants born to mothers using kratom during pregnancy, with symptoms resembling opioid withdrawal in newborns.
• Naloxone response: Kratom overdose can be managed similarly to opioid overdose, and naloxone may partially reverse respiratory depression, though results are inconsistent.

Related Compounds

• 7-Hydroxymitragynine — more potent but minor alkaloid; increasingly produced semisynthetically and sold in concentrated products
• Mitragynine pseudoindoxyl — synthetic derivative with extremely high μ-opioid affinity (Ki: 0.087 nM)
• Speciociliatine — second most abundant alkaloid in some kratom varieties
• Paynantheine — smooth muscle relaxant properties
• Rhynchophylline — NMDA antagonist also found in cat's claw (Uncaria tomentosa)